



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.
11183-003-999

APPLICATION NO
10/524,134

APPLICANT
Koenig et al.

FILING DATE
February 11, 2005

GROUP
1644

U.S. PATENT DOCUMENTS

MATTER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C.C.	A01	4,179,337	12/18/1979	Davis et al.			
	A02	5,711,944	01/27/1998	Gilbert et al.			
	A03	5,888,533	03/30/1999	Dunn			
	A04	5,648,260	07/15/1999	Winter et al.			
	A05	5,945,115	08/31/1999	Dunn et al.			
	A06	6,019,968	02/01/2000	Platz et al.			
	A07	6,132,764	10/17/2000	Li et al.			
	A08	6,194,551	02/27/2001	Idusogie et al.			
	A09	6,218,149	04/17/2001	Morrison et al.			
	A10	2001/0036459	11/01/2001	Ravetch			
	A11	6,339,069	01/15/2002	Meers et al.			
	A12	2002/0028486	03/07/2002	Morrison et al.			
	A13	6,420,149	07/16/2002	Fukuda et al.			
	A14	6,472,511	10/29/2002	Leung et al.			
	A15	6,528,624	03/04/2003	Idusogie et al.			
	A16	2003/0115614	06/19/2003	Kanda et al.			
C-C.	A17	5,837,243	11/17/1997	Deo et al.			

FOREIGN PATENT DOCUMENTS

MATTER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
C.C.	B01	WO 94/18330 A1	08/18/1994	PCT				
	B02	WO 99/58572 A1	11/18/1999	PCT				
	B03	WO 00/42072 A1	07/20/2000	PCT				
	B04	WO 01/79299 A1	10/25/2001	PCT				
	B05	WO 03/035835 A2	05/01/2003	PCT				
	B06	WO 03/066095 A2	08/14/2003	PCT				
	B07	EP 0 359 096 B1	11/05/1997	EPC				
	B08	EP 1 006 183 A1	06/07/2000	EPC				
C-C.	B09	EP 0 343 950 B1	10/18/2000	EPC				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C.C.	C01	Abra et al., The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res. 2002 Feb-May;12(1-2):1-3
	C02	Bendas G, Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs. 2001;15(4):215-24.
C.C.	C03	Billadeau et al., ITAMs versus ITIMs: striking a balance during cell regulation, J Clin Invest. 2002 Jan;109(2):161-8

C.C.	C04	Bolland and Ravetch., Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol. 1999;72:149-177
	C05	Bolland et al., Genetic modifiers of systemic lupus erythematosus in FcγRIIB(-/-) mice. J Exp Med. 2002 May 6;195(9):1167-74
	C06	Boruchov et al., Expression and modulation of the inhibitory Fcγ receptor, FcγRIIb (CD32b), on human dendritic cells (DCs). Laboratory of Cellular Immunobiology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY, NY 10021
	C07	Brauweiler et al., Partially distinct molecular mechanisms mediate inhibitory FcγRIIB signaling in resting and activated B cells. J Immunol. 2001;167:204-211
	C08	Brown EJ., In vitro assays of phagocytic function of human peripheral blood leukocytes: receptor modulation and signal transduction. Methods Cell Biol. 1994;45:147-164
	C09	Budde et al., Specificity of CD32 mAb for FcγRIIa, FcγRIIb1, and FcγRIIb2 expressed in transfected mouse B cells and BHK-21 cells. Leukocyte Typing V: White cell differentiation antigens. 1995;828-832 (Schlossman, Bousmell, Gilks, Harlan, Kishimoto, eds.)
	C10	Callanan et al., The IgG Fc Receptor, FcγRIIB is a target for deregulation by chromosomal translocation in malignant lymphoma. PNAS. 2000 Jan;97(1):309-314.
	C11	Cameron et al., Differentiation of the human monocyte cell line, U937, with dibutyryl cyclicAMP induces the expression of the inhibitory Fc receptor, FcγRIIb. Immunol Lett. 2002 Oct 1;83(3):171-9
	C12	Camilleri-Broët et al., FcγRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. Br J Haematol. 2004;124(1):55-62
	C13	Cassard et al., Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells. The J Clin Invest. 2002 November;110(10):1549-1557
	C14	Chappel et al., Identification of the FCγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc. Natl. Acad. Sci. USA. 1991 October;88(20):9036-9040
	C15	Clynes et al., Inhibitory Fc receptors modulate <i>in vivo</i> cytotoxicity against tumor targets. Nat Med 2000;6(4):443-6
	C16	Damle et al., B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002 June 1;99(11):4087-4093
	C17	Davies et al., Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγRIII. Biotechnol Bioeng. 2001 Aug 20;74(4):288-94
	C18	Daeron et al., The Same Tyrosine Based Inhibition Motif, in the Intracytoplasmic Domain of FcγRIIB, regulates negatively BCR, TCR- and FcR dependent cell activation. Immunity. 1995 Nov;3: 635-646
	C19	Ding et al., Inhibition of the function of the FcγRIIB by a monoclonal antibody to thymic shared antigen-1, a Ly-6 family antigen. Immunology. 2001 Sep;104(1):28-36
	C20	Eppstein et al., Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor. Proc Natl Acad Sci U S A. 1985 Jun;82(11):3688-92
	C21	Fanger et al., Production and use of anti-FcR bispecific antibodies. Immunomethods. 1994 Feb;4(1):72-81
	C22	Farag, et al., FcγRIIIa and FcγRIIIa polymorphisms do not predict response to Rituximab in B-cell chronic lymphocytic leukemia. Blood. 2003 Oct 16 (15 pp.)
	C23	Fidler, I. J., Macrophages and metastasis--a biological approach to cancer therapy. Cancer Res. 1985 Oct;45(10):4714-26.
	C24	Gerber et al., Stimulatory and inhibitory signals originating from the macrophage Fcγ receptors. Microbes Infect. 2001 Feb;3(2):131-9
	C25	Holmes et al., Alleles of the Ly-17 alloantigen define polymorphisms of the murine IgG Fc receptor. Proc Natl Acad Sci USA. 1985 Nov;82(22):7706-10
	C26	Hwang et al., Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study. Proc Natl Acad Sci U S A. 1980 Jul;77(7):4030-4
	C27	Isaacs et al., Therapy with monoclonal antibodies. II. The contribution of Fcγ receptor binding and the influence of C _H 1 and C _H 3 domains on <i>in vivo</i> effector function. The Journal of Immunology. 1998;161:3862-3869
	C28	Jefferis et al., Recognition sites on human IgG for Fcγ receptors: the role of glycosylation. Immunol Lett. 1995 Jan;44(2-3):111-7
	C29	Kagari et al., Essential Role of Fcγ Receptors in anti-type II collagen antibody induced arthritis. J. Immunol. Apr. 2003;170:4318-24
	C30	Lifely et al., Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology. 1995 Dec;5(8):813-22
	C31	Lin et al., Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193(6):727-739.
	C32	Lin et al., The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia. 2002;7(2):147-62
	C33	Lyden et al., The Fc receptor for IgG expressed in the villus endothelium of human placenta is FcγRIIb2. J Immunol. 2001 Mar 15;166(6):3882-9
	C34	Malbec et al., Fcγ receptor I-associated <i>lyn</i> -dependent phosphorylation of Fcγ receptor IIB during negative regulation of mast cell activation. J Immunol. 1998 Feb 15;160(4):1647-58
C.C.	C35	Maruyama K, <i>In vivo</i> targeting by liposomes. Biol Pharm Bull. 2000 Jul;23(7):791-9

C36	Metcalf, Mast Cells. <i>Physiol Rev.</i> 1997 Oct;77(4):1033-79
C37	Micklem et al., Different isoforms of human FcRII distinguished by CDw32 antibodies. <i>J Immunol.</i> 1990 March;144:2295-2303
C38	Nakamura et al., Fcγ receptor IIB-deficient mice develop Goodpasture's Syndrome upon immunization with Type IV collagen: a novel murine model for Autoimmune Glomerular Basement Membrane Disease. <i>J. Exp. Med.</i> 2000 March 6;191(5):899-905
C39	Norris et al., A naturally occurring mutation in FcγRIIA: A Q to K ¹²⁷ change confers unique IgG binding properties to the R ¹³¹ allelic form of the receptor. <i>Blood.</i> 1998 January 15;91(2):656-662
C40	Ott et al., Downstream of Kinase, p62 ^{cas} , is a mediator of FcγRIIB inhibition of FcεRI signaling. <i>J. of Immunol.</i> 2002;168:4430-9
C41	Park et al., Immunoliposomes for cancer treatment. <i>Adv Pharmacol.</i> 1997;40:399-435
C42	Park YS, Tumor-directed targeting of liposomes. <i>Biosci Rep.</i> 2002 Apr;22(2):267-81
C43	Presta LG, Engineering antibodies for therapy. <i>Curr Pharm Biotechnol.</i> 2002 Sep;3(3):237-56
C44	Priscop et al., Differential modulation of stimulatory and inhibitory Fcγ receptors on human monocytes by Th1 and Th2 cytokines. <i>J Immunol.</i> 2001 Jan 1;166(1):531-7
C45	Pulford et al., A new monoclonal antibody (KB61) recognizing a novel antigen which is selectively expressed on a subpopulation of human B lymphocytes. <i>Immunology.</i> 1986 Jan;57(1):71-6
C46	Qin et al., Fcγ receptor IIB on follicular dendritic cells regulates the B cell recall response. <i>J Immunol.</i> 2000;164:6268-6275
C47	Ravetch and Bolland, IgG Fc receptors. <i>Annu Rev Immunol.</i> 2001;19:275-290
C48	Ravetch et al., Fc Receptors. <i>Annu Rev Immunol.</i> 1991;9:457-92
C49	Ravetch et al., Fc receptors: rubor redux. <i>Cell.</i> 1994 Aug 26;78(4):553-60
C50	Ravetch et al., Immune inhibitory receptors. <i>Science.</i> 2000 Oct 6;290(5489):84-9.
C51	Real et al., IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. <i>Cancer Res.</i> 2001;61(14): 5517-22
C52	Routledge et al., The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. <i>Transplantation.</i> 1995 Oct 27;60(8):847-53
C53	Samuelsson et al., Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. <i>Science.</i> 2001 January 19; 291:484-486
C54	Sarkar et al., Negative signaling via FcγRIIB1 in B cells blocks phospholipase Cγ2 tyrosine phosphorylation but not Syk or Lyn activation. <i>J Biol Chem.</i> 1996 Aug 16;271(33):20182-6
C55	Scholl et al., Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis? <i>Mol Carcinog.</i> 7(4):207-11
C56	Shields et al., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. <i>J Biol Chem.</i> 2002 Jul 26;277(30):26733-40
C57	Sondermann et al., The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. <i>Nature.</i> 2000 Jul 20;406(6793):267-273
C58	Tam et al., A bispecific antibody against human IgE and human FcγRII that inhibits antigen-induced histamine release by human mast cells and basophils. <i>Allergy</i> 2004;59:772-780
C59	Tao and Morrison, Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. <i>J Immunol.</i> 1989 Oct 15;143(8):2595-601
C60	Todorovska et al., Design and application of diabodies, triabodies and tetrabodies for cancer targeting. <i>J Immunol Methods.</i> 2001 Feb 1;248(1-2):47-66
C61	Tridandapani et al., Regulated Expression and Inhibitory Function of FcγRIIb in Human Monocytic Cells, <i>Journal of Biol. Chem.</i> 277(7):50582-9
C62	Umaña et al., Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. <i>Nat Biotechnol.</i> 1999 Feb;17(2):176-80
C63	Van Nguyen et al., Colony stimulating factor-1 is required to recruit macrophages into the mammary gland to facilitate mammary ductal outgrowth. <i>Dev Biol.</i> 2002;247(1):11-25
C64	Van Sorge et al., FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. <i>Tissue Antigens.</i> 2003;61:189-202
C65	Vingerhoeds et al., Immunoliposomes in vivo. <i>Immunomethods.</i> 1994 Jun;4(3):259-72
C66	Wallick et al., Glycosylation of a VH residue of a monoclonal antibody against α (1→6) dextran increases its affinity for antigen. <i>J Exp Med.</i> 1988 Sep 1;168(3):1099-109
C67	Warmerdam et al., Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). <i>J Exp Med.</i> 1990 Jul 1;172(1):19-25
C68	Weinrich et al., Epitope mapping of new monoclonal antibodies recognizing distinct human FcRII (CD32) isoforms. <i>Hybridoma</i> 1996 Nov 2; 15:109-116
C69	Wright and Morrison, Effect of glycosylation on antibody function: implications for genetic engineering. <i>Trends Biotechnol.</i> 1997 Jan;15(1):26-32
C70	Xu et al., FcγRs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody Based Therapeutics. <i>J Immunol.</i> 2003;171:562-68

C.C.	C71	Xu et al., Residue at position 331 in the IgG1 and IgG4 C _H 2 domains contributes to their differential ability to bind and activate complement. The Journal of Biological Chemistry, 1994 Feb 4;269(5):3469-3474
EXAMINER	<i>er of</i>	DATE CONSIDERED 3/23/06
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		